BSG Specific Neutra™ Antibody Products
Product listBasigin (Ok Blood Group), BSG, serves as a crucial type I integral membrane receptor involved in spermatogenesis, monocarboxylate transporter expression, neural network formation, and tumor advancement. Additionally, BSG belongs to the immunoglobulin superfamily and exhibits ubiquitous expression across diverse tissues. Conditions linked with BSG encompass ameloblastoma and measles.
Its Gene ID: 682, UniProtKB ID: P35613, and OMIM ID: 109480.
BSG Signaling Pathway
Enriched on the tumor cell surface, BSG, alias CD147, emerges as a pivotal factor in tumor-stroma interactions, stimulating adjacent stromal cells to enhance the synthesis of various Matrix metalloproteinases (MMPs). In melanoma, BSG is demonstrated to elevate MMP-1, MMP-2, and MMP-3 levels, while in breast cancer, it upregulates MMP-9 expression, while leaving tissue inhibitors of MMPs, TIMP-1 and TIMP-2, unaffected. Stimulation of MMP-9 leads to the degradation of type IV collagen, enhancing the metastasis and invasion of breast cancer cells. Moreover, BSG induces the urokinase plasminogen activator system (uPA/uPAR/PAI-1) expression in melanoma, breast, and ovarian tumor cells, thereby augmenting their proteolytic and invasive potential in vitro and in vivo. Additionally, the interaction between BSG and hyaluronan-CD44 modulates the invasive properties of breast cancer cells through activation of the EGFR–RAS–ERK pathway.
Fig.1 BSG/CD147 interacting partners, signaling pathways, and microenvironmental interactions in cancer progression.1, 2
Applications of Anti-BSG Antibodies
- Anti-BSG MAb Enables Noninvasive Detection and Imaging of Tumors
In the physiologic state, extracellular matrix metalloproteinase inducer BSG, a glycoprotein situated on the cellular periphery, demonstrates scanty manifestation within typical epithelial and embryonic tissues, yet manifests markedly elevated levels within diverse malignancies known for their aggressive behavior. BSG has been implicated in pan-cancer immunity and progression. Accurate detection of BSG expression in tumors and monitoring its changes during therapy are essential for the development of BSG-targeting therapeutic strategies. In a study, a novel radiotracer is constructed by labeling the anti-BSG monoclonal antibody (mAb) with radionuclide 124/125I for the noninvasive detection of BSG expression in pan-cancers. The physicochemical properties, affinity, metabolic characteristics, biodistribution, and immunoPET imaging are characterized. High BSG expression is observed in colon cancer cells, human pharyngeal squamous cancer cells, and human prostate cancer cells, whereas low expression is found in human pancreatic cancer cells and human gastric cancer cells. In conclusion, 124/125I-anti-BSG demonstrates a high affinity for BSG and holds the potential for imaging BSG-positive tumors. The emergence of 124I-anti-BSG holds promise for illuminating the intricacies of tumor microenvironment modulation and shaping tailored diagnostic and therapeutic strategies for neoplasms.
- Application of Anti-BSG Antibodies to Inhibit SARS-Cov-2 Virus Infection
SARS-CoV-2 has disseminated globally, entering host cells through a novel pathway involving the interaction between BSG and the spike protein (SP). In vitro antiviral assays have demonstrated that a humanized anti-BSG antibody significantly inhibited viral entry into host cells. The interaction between BSG and SP exhibits high affinity, as confirmed by co-immunoprecipitation and ELISA. Immuno-electron microscopy has further revealed the localization of BSG and SP in SARS-CoV-2 infected Vero E6 cells. Thus, identifying the BSG-SP pathway as a mechanism for SARS-CoV-2 entry highlights a crucial target for developing specific antiviral therapies.
Creative Biolabs offers a collection of more than 30 meticulously engineered anti-BSG antibodies, produced using recombinant techniques. Moreover, personalized customization services are accessible to adapt neutralizing antibodies targeting BSG to precise specifications.
REFERENCES
- Landras, Alexandra, et al. "CD147 is a promising target of tumor progression and a prognostic biomarker." Cancers 11.11 (2019): 1803.
- Distributed under Open Access license CC BY 4.0, without modification.
